HUGE -- Oversold COVID-19 play; insiders buying at premium

I am in at $2.35.
- Oversold, RSI @ 21
- $9.5 USD financing just closed at $3.10 CDN with insiders/institutions buying ahead of COVID-19 treatment Phase 2 trial results
- Will need to maintain $4+ stock price to stay listed on NASDAQ
- Gaps above at 3.33 & 5.56
- Signs of bottoming out
- $25M in cash; with Cannabis asset sale (~$20M), the cash position will exceed market cap
- Due for COVID-19 treatment Phase 2 trial results within a week or two